Refine your search with our Advanced Search Tool
Listing contains 128 trial(s)
Cervical Cancer
Phase III
GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation vs. Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Study Number: 06-128 |
Endometrial Cancer
Pilot
Surgery for endometrial cancer: Biobehavioral analysis of sleep, stress and pain Study Number: 09-027 |
Tissue and/or blood banking study
GDP: Tissue and Data Acquisition Activity for the Study of Gynecologic Disease (GOC 04-124) Study Number: 04-124 |
Fallopian Tube Cancer
Lab
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer HOPE (Hormones and Ovarian Cancer Prediction) Study Number: 04-032 |
Phase I
OX-06-009: PHASE I DOSE-ESCALATION PARALLEL STUDY OF INTRAVENOUS DOCETAXEL/INTRAPERITONEAL OXALIPLATIN AND INTRAPERITONEAL DOCETAXEL/INTRAVENOUS OXALIPLATIN IN PLATINUM-SENSITIVE AND PLATINUM-RESISTANT RECURRENT OVARIAN, PRIMARY PERITONEAL, AND FALLOPIAN TUBE CANCER (GYN-ONC# 07-05) Study Number: 07-045 |
Prospective/Retrospective Study
A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (GOC 05-005) Study Number: 05-080 |
Tissue and/or blood banking study
GDP: Tissue and Data Acquisition Activity for the Study of Gynecologic Disease (GOC 04-124) Study Number: 04-124 |
Ovarian Epithelial Cancer
Lab
Acquisition of Blood and Tissue Samples for Research Purposes (G0C# 22-096) Study Number: 04-202 |
Phase II
A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma Study Number: 07-081 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with First Platinum-Resistant or Refractory Relapsed Ovarian Cancer Study Number: 08-141 |
Phase III
GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or XYOTAXTM (CT-2103) (IND 70177) vs. No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieved a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (NCI Version 01 27 05) (GOC 05-004) Study Number: 05-068 |
A PHASE III CLINICAL TRIAL OF BEVACIZUMAB WITH IV VERSUS IP CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CARCINOMA NCI-SUPPLIED AGENT(S): BEVACIZUMAB Study Number: 09-074 |
Prospective/Retrospective Study
A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (GOC 05-005) Study Number: 05-080 |
Ovarian Germ Cell Tumor
Lab
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer HOPE (Hormones and Ovarian Cancer Prediction) Study Number: 04-032 |
Ovarian Low Malignant Potential Tumor
Phase II
A Single Arm Open Label, Phase II Study to Assess the Safety and Eficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascities (GOC 06-03) Study Number: 06-018 |
Ovarian Sarcoma
Registry
Magee-Womens Hospital of the University of Pittsburgh Medical Center Women's Cancer and Cancer-Like Disorders Registry (Gyn-- Onc# 23-071) Study Number: 07-137 |
Tissue and/or blood banking study
Acquisition of Blood Samples and Tissue for Research Purposes (Gyn-Onc# 22-096) Study Number: 07-058 |
